FDG PET-CT aids in the preoperative assessment of patients with newly diagnosed thymic epithelial malignancies

Journal of Thoracic Oncology

Volumn 8, Issue 4, 2013, Pages 502-510

  Benveniste, Marcelo F K ^a   Moran, Cesar A ^a   Mawlawi, Osama ^a   Fox, Patricia S ^a   Swisher, Stephen G ^a   Munden, Reginald F ^a   Marom, Edith M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Masaoka Koga; PET CT; Thymoma

Indexed keywords

FLUORODEOXYGLUCOSE;

ADULT; AGED; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER STAGING; CARCINOID; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RANK SUM TEST; RETROSPECTIVE STUDY; REVIEW; THYMUS CANCER; THYMUS CARCINOID;

EID: 84875391571     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182835549     Document Type: Article

References (40)

1. Duwe BV, Sterman DH, Musani AI. Tumors of the mediastinum. Chest 2005;128:2893-2909
2. Casey EM, Kiel PJ, Loehrer PJ Sr. Clinical management of thymoma patients. Hematol Oncol Clin North Am 2008;22:457-473
3. Blumberg D, Port JL, Weksler B, et al. Thymoma: A multivariate analysis of factors predicting survival. Ann Thorac Surg 1995;60:908-913; discussion 914
4. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: Dualmodality PET/CT in preoperative staging. Radiology 2003;229:526-533
5. Shim SS, Lee KS, Kim BT, et al. Non-small cell lung cancer: Prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005;236:1011-1019
6. Endo M, Nakagawa K, Ohde Y, et al. Utility of 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors. Lung Cancer 2008;61:350-355
7. Sung YM, Lee KS, Kim BT, Choi JY, Shim YM, Yi CA. 18F-FDG PET/ CT of thymic epithelial tumors: Usefulness for distinguishing and staging tumor subgroups. J Nucl Med 2006;47:1628-1634
8. Koga K, Matsuno Y, Noguchi M, et al. A review of 79 thymomas: Modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int 1994;44:359-367
9. Travis WD, Brambilla E, Muller-Hermelik HK, et al. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press, 2004
10. Shankar LK, Hoffman JM, Bacharach S, et al.; National Cancer Institute. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 2006;47:1059-1066
11. Detterbeck F, Youssef S, Ruffini E, Okumura M. A review of prognostic factors in thymic malignancies. J Thorac Oncol 2011;6(7 Suppl 3):S1698-S1704
12. Kaira K, Sunaga N, Ishizuka T, Shimizu K, Yamamoto N. The role of fluorodeoxyglucose positron emission tomography in thymic epithelial tumors. Cancer Imaging 2011;11:195-201
13. Igai H, Matsuura N, Tarumi S, et al. Usefulness of [18F]fluoro-2-deoxy-D- glucose positron emission tomography for predicting the World Health Organization malignancy grade of thymic epithelial tumors. Eur J Cardiothorac Surg 2011;40:143-145
14. Kaira K, Endo M, Abe M, et al. Biologic correlation of 2-[18F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol 2010;28:3746-3753
15. Kumar A, Regmi SK, Dutta R, et al. Characterization of thymic masses using (18)F-FDG PET-CT. Ann Nucl Med 2009;23:569-577
16. Sasaki M, Kuwabara Y, Ichiya Y, et al. Differential diagnosis of thymic tumors using a combination of 11C-methionine PET and FDG PET. J Nucl Med 1999;40:1595-1601
17. Shibata H, Nomori H, Uno K, et al. 18F-fluorodeoxyglucose and 11C-Acetate positron emission tomography are useful modalities for diagnosing the histologic type of thymoma. Cancer 2009;115:2531-2538
18. Terzi A, Bertolaccini L, Rizzardi G, et al. Usefulness of 18-F FDG PET/ CT in the pre-Treatment evaluation of thymic epithelial neoplasms. Lung Cancer 2011;74:239-243
19. Luzzi L, Campione A, Gorla A, et al. Role of fluorine-flurodeoxyglucose positron emission tomography/computed tomography in preoperative assessment of anterior mediastinal masses. Eur J Cardiothorac Surg 2009;36:475-479
20. Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med 2009;50(Suppl 1):11S-20S.
21. Suster S, Moran CA. Histologic classification of thymoma: The World Health Organization and beyond. Hematol Oncol Clin North Am 2008;22:381-392
22. Moran CA, Walsh G, Suster S, Kaiser L. Thymomas II: A clinicopathologic correlation of 250 cases with a proposed staging system with emphasis on pathologic assessment. Am J Clin Pathol 2012;137:451-461
23. Moran CA, Weissferdt A, Kalhor N, et al. Thymomas I: A clinicopathologic correlation of 250 cases with emphasis on the World Health Organization schema. Am J Clin Pathol 2012;137:444-450
24. Chen G, Marx A, Chen WH, et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors: A clinicopathologic study of 200 thymoma cases from China. Cancer 2002;95:420-429
25. Fang W, Chen W, Chen G, Jiang Y. Surgical management of thymic epithelial tumors: A retrospective review of 204 cases. Ann Thorac Surg 2005;80:2002-2007
26. Lee HS, Kim ST, Lee J, et al. A single institutional experience of thymic epithelial tumours over 11 years: Clinical features and outcome and implications for future management. Br J Cancer 2007;97:22-28
27. Marom EM, Milito MA, Moran CA, et al. Computed tomography findings predicting invasiveness of thymoma. J Thorac Oncol 2011;6:1274-1281
28. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009;50(Suppl 1):122S-150S.
29. Al-Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 2004;14:43-47
30. Huff CA, Matsui W, Smith BD, Jones RJ. The paradox of response and survival in cancer therapeutics. Blood 2006;107:431-434
31. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-1037
32. Matsui W, Wang Q, Barber JP, et al. Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Res 2008;68 190-197
33. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of wholebody total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology 2012;264:559-566
34. Liu F, Zhao B, Krug LM, et al. Assessment of therapy responses and prediction of survival in malignant pleural mesothelioma through computeraided volumetric measurement on computed tomography scans. J Thorac Oncol 2010;5:879-884
35. Al-Sarraf N, Gately K, Lucey J, et al. Clinical implication and prognostic significance of standardised uptake value of primary non-small cell lung cancer on positron emission tomography: Analysis of 176 cases. Eur J Cardiothorac Surg 2008;34:892-897
36. Berghmans T, Dusart M, Paesmans M, et al.; European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): A systematic review and meta-Analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008;3:6-12
37. Sharif S, Zahid I, Routledge T, Scarci M. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg 2011;12:806-811
38. Zhang B, Li X, Lu X. Standardized uptake value is of prognostic value for outcome in head and neck squamous cell carcinoma. Acta Otolaryngol 2010;130:756-762
39. Costelloe CM, Macapinlac HA, Madewell JE, et al. 18F-FDG PET/CT as an indicator of progression-free and overall survival in osteosarcoma. J Nucl Med 2009;50:340-347
40. Kaira K, Murakami H, Miura S, et al. 18F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors. Ann Nucl Med 2011;25:247-253